Core F: Biomarker Core

摘要：生物标志物核心 Biomarker Core为堪萨斯大学阿尔茨海默氏症进行流体生物标记物评估 疾病研究中心(KU ADRC)。对于队列参与者，我们确定了淀粉样蛋白-tau-神经变性 (ATN)在脑脊液(CSF)和血浆中的水平；测量血浆炎症、神经营养因子和 并获得血液和脑线粒体DNA(MtDNA)序列。 除了满足该中心对标准ATN生物标记物评估的需求外，Biomarker Core 保持我们基础线粒体基因组和新陈代谢的创新和独特资源 (米高梅)核心。米高梅核心公司开发了新的线粒体和代谢生物标记物，并使用了这些 生物标记物作为临床试验的目标参与终点。它还确定了线粒体和新陈代谢- 相关的诊断和预后生物标志物。最初的米高梅酷睿也提供了最先进的 为调查人员提供咨询和技术支持，而在这里，Biomarker Core提供这些服务。细胞 可通过MGM核心获得的模型包括细胞质杂交(胞质杂交体)细胞系，诱导多能性 干细胞(IPSC)系、从IPSC分化的神经元和神经胶质细胞以及淋巴母细胞系仍可用 通过Biomarker Core。 增加ATN评估丰富了我们的临床队列数据集，并培育了整个领域的新兴ADRD 对ATN生物标记物与线粒体DNA签名、线粒体功能和能量代谢的关联感兴趣。 将这些服务扩展到研究人员将使他们的研究项目和计划受益。它提供了我们本地的， 为国内外用户提供备受重视的新陈代谢导向服务、专业技术和试剂WORE 在我们之前的两个周期中提供。它保持了我们在理解阿尔茨海默病病因方面的卓越地位 线粒体和能量代谢障碍，这种障碍的后果，以及如何 以治疗或预防的目的操纵线粒体和能量代谢。在这个周期中， BioMarker Core将通过专注于以下具体目标来实现其目标：(1)执行流体和 组织生物标记物评估；(2)追求线粒体和代谢生物标记物的开发；以及(3) 提供细胞模型、技术服务和新型生物标记物。

ABSTRACT: BIOMARKER CORE The Biomarker Core performs fluid biomarker assessments for the University of Kansas Alzheimer's Disease Research Center (KU ADRC). For Cohort participants we determine amyloid-tau-neurodegeneration (ATN) levels in cerebrospinal fluid (CSF) and plasma; measure plasma inflammation, neurotrophin, and metabolism-relevant endpoints; and obtain blood and brain mitochondrial DNA (mtDNA) sequences. In addition to meeting the Center's need for standard ATN biomarker assessments, the Biomarker Core maintains the innovation and unique resources of our foundational Mitochondrial Genomics and Metabolism (MGM) Core. The MGM Core developed novel mitochondrial and metabolism biomarkers and used those biomarkers as clinical trial target engagement endpoints. It also identified mitochondria and metabolism- associated diagnostic and prognostic biomarkers. The original MGM Core also offered state-of-the-art consultation and technical support to investigators and here the Biomarker Core delivers these services. Cell models available through the MGM Core including cytoplasmic hybrid (cybrid) cell lines, induced pluripotent stem cell (iPSC) lines, neurons and glia differentiated from iPSCs, and lymphoblast cell lines remain available through the Biomarker Core. Adding ATN assessments enriches our Clinical Cohort dataset and nurtures an emerging ADRD field-wide interest in correlating ATN biomarkers with mtDNA signatures, mitochondrial function, and energy metabolism. Extending these services to investigators benefits their research projects and programs. It provides our local, national, and international users the much-valued metabolism-oriented service, expertise and reagents we provided during our previous two cycles. It maintains our preeminence in understanding the causes of AD mitochondrial and energy metabolism dysfunction, the consequences of that dysfunction, and how to manipulate mitochondria and energy metabolism with therapeutic or prevention intent. During this cycle the Biomarker Core will accomplish its goals by focusing on the following Specific Aims: (1) Perform fluid and tissue biomarker assessments; (2) Pursue mitochondrial and metabolism biomarker development; and (3) Provide cell models, technical services, and novel biomarkers.